glp-1 amylin Chronic combination therapy of and GLP-1R analogs results in Combined GLP-1/amylin analog bests monotherapy

IUPHAR review - Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target

Mitochondrial Uncouplers: Increasing energy expenditure by targeting mitochondrial function is another area of research, with companies like Rivus Therapeutics (HU6) and OrsoBio (TLC-6740) exploring this mechanism

Compared with current use (20%) of SGLT2is, widespread use (75%) in the total population with type 2 diabetes was projected to prevent 13,376 non-fatal MIs, 117,240 HF hospitalisations, 6871 ESKD events and 35,989 deaths, but increase the number of non-fatal strokes by 1363 (Table 2)

This magic and powerful antioxidant is not just your wellness trend